Crescom, Mass General Brigham Launch PoC of Pediatric Musculoskeletal AI

Crescom, a medical AI company specializing in musculoskeletal analysis, has launched a global clinical PoC of its pediatric musculoskeletal AI solutions in collaboration with the Department of Radiology at Mass General Brigham.

The validation study covers three core solutions:

• Bone age analysis AI MediAI-BA (FDA 510(k) cleared)
• Full lower-limb length measurement AI MediAI-SG
• Scoliosis severity auto-measurement AI MediAI-SC

Mass General Brigham radiologists will compare AI-generated readings against expert clinical interpretations, conducting a comprehensive assessment of clinical validity and real-world usability. User feedback will also be collected from the U.S. clinical environment to refine the solutions and establish a base for local commercialization.

Clinical fields are showing increased interest in optimizing operational workflows through AI-driven automated analysis. Through this clinical validation study, Crescom aims to objectively demonstrate that its musculoskeletal AI technology can substantively improve the reading efficiency of medical specialists.

The collaboration with Mass General Brigham will serve as a milestone for Crescom to establish a robust clinical track record in the North American radiology and pediatric growth clinical markets while growing its network with key local healthcare institution. The company also plans to pioneer high-value business domains by integrating its pediatric musculoskeletal analysis and growth prediction solutions with the North American youth development industry.

“Building on the upcoming results of this validation, we will aggressively expand our footprint across the North American market,” said Jae Joon Lee, CEO of Crescom.